We treated two ER-positive Luminal breast cancer cell lines, T47D and ZR75-1, with tamoxifen, the most widely used nonsteroidal selective ER modulator for adjuvant therapy of ER-positive breast cancer. This evidence concerns the gene ESR1 and breast cancer.